Dr. Françoise Degoul currently serves as a Researcher at the Institut National de la Santé et de la Recherche Médicale (INSERM), France. She graduated in molecular and cellular biology with a health sciences specialty at the University Blaise Pascal in Clermont-Ferrand with a PhD in 1991. In her post-doc performed in Paris (1992-1993), her research was focused on understanding the consequences of intriguing mutations occurring in not all mtDNA molecules. After successful application for the INSERM position in 1994, she worked more specifically on mitochondrial tRNA mutations. In 1998, she joined Dr. D Pessayre’s’ lab (INSERM U481) and worked on mtDNA deletions found in alcoholic hepatic diseases and their association with oxidative stress. In 2002, she went back to Clermont-Ferrand to join a team (INSERM U484) working on the development of new approaches for cancer imaging and treatment and focused on the pharmacologic development of small molecules and on targeted radionuclide therapy using small molecules, antibodies and nanoparticles. Looking for new cancer "targets”, she came to work on annexin A1's role in melanoma and then on inflammation. She managed a team named “Targets and Tools for Imaging and Therapy” (2017-2020) in the IMoST research unit (UMR1240, INSERM UCA). Recently, she joined the iGRED (INSERM U1103, CNRS 6293, UCA) and a new team dedicated to nuclear receptors in prostate diseases.